Lilly is betting big on retatrutide as the next pillar of its obesity portfolio after its weight loss injection Zepbound and ...
The U.S. Food and Drug Administration expanded the use of Rhythm Pharmaceuticals’ therapy for a rare form of obesity caused ...
As Eli Lilly begins to take the next generation of obesity drugs to regulators this year, a lower-profile collaboration ...
Imcivree’s approval in a type of obesity driven by brain injury could unlock an opportunity Wall Street analysts believe to ...
A Phase III trial of Rhythm Pharmaceuticals’ Imcivree (setmelanotide) failed to meet its primary endpoints in four rare, ...
Obesity is a chronic disease that can significantly affect an individual’s overall health. In this Care Cues, experts discuss ...
Rhythm Pharmaceuticals is switching up the tempo for its melanocortin-4 receptor (MC4R) agonist Imcivree. | The new FDA nod makes Rhythm Pharma's Imcivree the first approved drug for acquired ...
At its peak, Imcivree’s sales in hypothalamic obesity could reach over $2 billion worldwide, according to analysts at Stifel.
Obesity increases the body's need for insulin, forcing cells in the pancreas known as beta cells to ramp up insulin ...
A new Pediatrics study is putting a spotlight on something most parents don’t think about when it comes to kids’ health: ...
Type 2 diabetes (T2D) and obesity are metabolic conditions with many causes, including overlapping and distinct genetic ...
Current childhood obesity prevention programs mostly focus on nutrition education and physical activity, which too often fail ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results